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Abstract
Alcoholic liver diseases (ALD) comprise a spectrum of clinical disorders and changes in liver 
tissue that can be detected by pathology analysis. These range from steatosis to more severe signs 
and symptoms of liver disease associated with inflammation, such as those observed in patients 
with alcoholic hepatitis or cirrhosis. Although the relationship between alcohol consumption and 
liver disease is well established, severe alcohol-related morbidities develop in only a minority of 
people who consume alcohol in excess. Inter-individual differences in susceptibility to the toxic 
effects of alcohol have been extensively studied—they include pattern of alcohol consumption, 
sex, environmental factors (such as diet), and genetic factors, which vary widely among different 
parts of the world. ALD is becoming more common in many parts of Asia but is decreasing in 
Western Europe. Treatment approaches, including availability of medications, models of care, and 
approach to transplantation, differ among regions.
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Alcohol is consumed worldwide and has been used in many cultures for centuries1. When 
consumed in excess, it can cause diseases that place social and economic burdens on 
societies. In 2012, about 3.3 million deaths, or 5.9% of all global deaths, were attributed to 
alcohol consumption1. Alcohol-related health disorders are generally determined by the 
volume and quality of alcohol consumed and the pattern of drinking1.
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Alcoholic liver disease (ALD) has been estimated to account for 48% of all deaths from 
cirrhosis2. It comprises a spectrum of disorders and pathologic changes in individuals with 
acute and chronic alcohol consumption, ranging from alcoholic steatosis to alcoholic 
hepatitis (AH) and cirrhosis. Alcoholic steatosis, once considered benign, is now recognized 
as a condition that may lead to advanced liver disease or cirrhosis3. Development of 
alcoholic steatosis depends on the dose and duration of alcohol intake. However, it is 
difficult to establish whether there is a threshold of alcohol intake required for development 
of fatty liver. Alcoholic steatosis can develop within 2–3 weeks in subjects who consume 
alcohol in the excessive range (120–150 g/day)4, but can be reversed with abstinence. If 
alcohol consumption continues, some patients develop AH—the most florid manifestation of 
ALD, associated with high mortality5. Approximately 15% to 20% of patients who drink 
alcohol excessively develop cirrhosis in their lifetime6.
Mortality from alcohol-associated cirrhosis in different countries correlates with per capita 
alcohol consumption7, 8. With recent changes in the economies and increases in average 
incomes in developing regions of the world, there has been a rapid rise in per capita alcohol 
consumption in countries such as China and India9,10. In fact, alcohol consumption is 
increasing faster in China than other parts of the world9, 11. The per capita consumption of 
alcohol in India has increased by 55% over the past decade10. Based on these statistics, it is 
expected that the prevalence of ALD will increase globally. We review the similarities and 
differences in epidemiologic factors, patterns of alcohol consumption, risk factors, and 
clinical features of patients with ALD in different geographic regions, comparing countries 
in Asia to those in Europe and the United States (US).
Patterns of Alcohol Consumption
In comparing similarities and differences of ALD among different regions of the world, it is 
important to understand current and evolving patterns of global alcohol consumption. The 
World Health Organization (WHO) reported that in 2010, total alcohol per capita 
consumption was highest in the developed world—mostly in the Northern Hemisphere12. 
Eastern Europe had the highest per capita consumption per year, with 15.7 liters per person 
(8.1 liters per woman and 24.9 liters per man)2. The US had per capita consumption with 9.2 
liters per person (4.9 liters per woman and 13.6 liters per man)12. By comparison, per capita 
consumption values for China, India, Republic of Korea, and Japan were 6.7 liters per 
person (2.2 liters per woman and 10.9 liters per man), 4.3 liters per person (0.5 liters per 
woman and 8 liters per man), 12.3 per person (3.9 in woman and 21 in man) and 7.2 liters 
per person (4.2 liters per woman and 10.4 liters per man), respectively12. The total adult per 
capita consumption in 2010, in liters of pure alcohol, is shown in Fig 113.
In general, men that consume up to 2 drinks/day (1 drink/day for women) are defined as 
moderate drinkers14. Drinking at this level does not increase risk of organ injury. Daily 
consumption beyond these limits is considered to be heavy drinking, which can have adverse 
health and social outcomes15. This definition of chronic drinkers does not include the pattern 
of binge drinking—the definition varies among different geographic regions. The US 
National Institute on Alcohol Abuse and Alcoholism proposed a definition of binge drinking 
as the consumption of 5 or more drinks for men (4 or more drinks for women) within 2 
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hrs16. In the United Kingdom (UK), binge drinking is defined as consuming 8 units or more 
for men (6 units or more for women; ~5 or 4 American standard drinks, respectively)17.
The WHO uses the patterns of drinking score (a composite measure of drinking patterns) to 
determine how people drink, instead of how much they drink, on a scale of 1 (least risky 
pattern of drinking) to 5 (most risky pattern of drinking)18. Parameters used to create this 
indicator include quantity of alcohol consumed per occasion, festive drinking, proportion of 
drinking events that result in becoming drunk, proportion of drinkers who drink daily, 
drinking with meals, and drinking in public places. Eastern Europe had the highest pattern of 
drinking score (4.9)2, whereas the score for the US was 2—similar to countries in Asia such 
as China, Japan, and Singapore18. India and Republic of Korea each had a score of 3.
In the US in 2013, 86.8% of people 18 years or older reported that they drank alcohol at 
some point in their lifetime. Of these people, 24.6% stated that they engaged in binge 
drinking and 6.8% reported that they engaged in heavy drinking in the past month19. The 
percentage of men who had at least 1 heavy drinking day in the past year decreased from 
31.6% in 1997 to 27.8% in 2006, then increased to 32.4% in 2009. Since the time period of 
2009 to 2014, there has been no decrease or increase20. In the UK, the Health Survey for 
England reported that 57% of young men were binge drinkers21. Most European countries 
have had the same trend toward an increase in binge drinking, even in southern countries14. 
In Asia, alcohol consumption in China is increasing faster than other parts of the world11. A 
recent national survey found 56% of men and 15% of women to be current drinkers. Among 
them, heavy drinking was reported in 63% of men and 51% of women, whereas binge 
drinking occurred for 57% of men and 27% of women11. Alcohol use disorders (AUDs), 
defined as harmful patterns of drinking such as alcohol dependence and abuse, have become 
a frequent problem linked to disturbances in mental and physical health and in social 
functioning in China11. There was a dramatic increase in the proportion of individuals with 
AUDs, from 0.45% in mid-1980s to 3.4% in mid-1990s,11 with the life-time prevalence of 
9% during the years of 2001 to 200522. India has also increased alcohol use, from 3.6 to 4.3 
liters/person/year13.
Unrecorded alcohol use varies greatly between countries, from below 10% in wealthy and 
highly regulated nations to above 50% in less well-developed nations23. Official statistics are 
typically based on taxation records of recorded consumption—these substantially 
underestimate total consumption, particularly in the developing world24. The chief concern 
regarding home brew is access to beverages with high alcohol content at relatively low cost. 
As a secondary concern, they may be contaminated with methanol, leading to life-
threatening poisonings or consumption of other hepatotoxins, such as 
polyhexamethyleneguanidine, which has been linked to an outbreak of acute cholestatic liver 
injury in Russia23.
Prevalence and Burden of ALD
Mortality from ALD, regardless of country, correlates with per capita of alcohol 
consumption7, 8. Overall consumption or average volume of alcohol consumed has been the 
usual measure of exposure, and that there is a dose-response relationship between the 
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volume of alcohol consumed and risk of ALD25. A meta-analysis found that consumption of 
more than 25 g/day increased the relative risk of cirrhosis26. This threshold is in accordance 
with that from a study showing a significant increase in risk of cirrhosis with alcohol 
consumption of more than 30 g/day27. A separate study showed that recent drinking, rather 
than earlier in life consumption, was associated with the risk of alcohol-associated 
cirrhosis28.
Although studies correlate average volume of alcohol consumption with ALD, several 
studies have associated risk with drinking patterns29. Binge drinking (too much too fast) and 
chronic excessive drinking (too much too often) are significant risk factors for ALD27, 30. In 
addition to the quantity of alcohol consumption, there is controversy over whether risk of 
ALD depends on the type and pattern of alcohol intake, independent of absolute levels of 
consumption. Some studies have found red wine drinkers to have a lower risk of ALD than 
consumers of other beverages28, 31. However, other studies produced contradicting 
results32, 33.
AH
The precise incidence and prevalence of AH are unknown, partly because AH may be 
completely asymptomatic and thus remain undiagnosed. The available data on the burden of 
AH from each geographic region are difficult to compare, primarily because of the disparity 
in the studied population. In a population-based cohort study of all patients with a hospital 
discharge diagnosis of AH in Denmark from 1999 to 2008, the overall incidence rate for AH 
was 36.6 per million/year34. The incidence was higher in men compared to women (46.4 vs 
26.9 per million/year, respectively). The incidence increased for men and women during the 
decade of study34. A study in France analyzed liver biopsies from 1604 subjects with 
chronic heavy alcohol use. Of these, 119 subjects (7.4%) had acute AH and 179 subjects 
(11%) had AH with cirrhosis35. In the US, total cases of AH-related hospitalization 
increased from 249,884 (0.66% of total admissions) in 2002 to 326,403 (0.83% of total 
admissions) in 2010, based on analysis of National Inpatient Sample data36. AH was found 
in ~29% of hospitalized patients with ALD in India37.
Alcohol-associated cirrhosis
The global burden of ALD, measured by deaths and disability-adjusted life years (DALYs), 
has been recently reported2. DALYs are an indicator of overall disease burden, providing the 
number of years lost due to poor health, disability, or early death. Globally, alcohol 
contributed 4.5% of all DALYs in 2004, making it the third leading risk factor for disease 
(after childhood underweight and unsafe sex), ahead of tobacco and other established risk 
factors38. Alcohol-attributable liver cirrhosis was responsible for 493,300 deaths (156,900 
deaths in women and 336,400 deaths in men) and 14,544,000 DALYs (4,112,000 DALYs for 
women and 10,432,000 DALYs for men) in 2010. It accounts for 0.9% of all global deaths 
(0.7% for women and 1.2% for men), 0.6% of all global DALYs (0.4% for women and 0.8% 
for men), 47.9% of all liver cirrhosis deaths (46.5% for women and 48.5% for men), and 
46.9% of all liver cirrhosis DALYs (44.5% for women and 47.9% for men)2. There were 
211.1 DALYs per 100,000 people caused by liver cirrhosis attributable to alcohol 
consumption in 20102. Central Asia experienced the greatest number of alcohol attributable 
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liver cirrhosis DALYs per 100,000 people for men and women, with 546.0 DALYs per 
100,000 people (435.1 DALYs per 100,000 women, and 655.0 DALYs per 100,000 men). 
Eastern Europe had the second highest rate of liver cirrhosis DALYs due to alcohol 
consumption, with 456.1 DALYs per 100,000 people2. Alcohol-attributable DALYS caused 
by liver cirrhosis in each geographic region is shown in Table 1.
The overall alcohol-attributable deaths from cirrhosis among different geographic regions is 
shown in Fig 2 (ref 2). Among western countries, time trends in mortality over the past 3 
decades have varied. Countries such as Austria, France, Germany, and Hungary have had a 
decrease in mortality, whereas Finland, Ireland, and the UK have had increases in 
mortality39. In the UK and Scotland, there was a 5-fold increase in cirrhosis mortality 
among men and 4-fold increase among women from 1950 through 200040, 41. In the past 40 
years, the UK has seen substantial reductions in the mortality of most common diseases 
whereas cirrhosis mortality has risen 5-fold—a striking exception42.
Factors Associated With ALD
In most of the studies from the US and Europe, the mean age of patients at the time of 
diagnosis with ALD has been 45–55 years old36, 35, 43, 44. Data from the US using the 
National Hospital Discharge Survey 2010 and National Inpatient Sample showed that most 
patients with a diagnosis of ALD were 45–64 years old,45 with the average age of 53 
years36. The age of diagnosis of patients with ALD in the US is similar to that from several 
countries in Europe35, 43, 44. The mean age at which ALD is detected in the western 
countries is older than that from a population-based study in China, which found most 
subjects with ALD to be 36–48 years old46. In a separate population-based study from 
China, Wang et al observed a trend of an increase in incidence of ALD as the population 
increased in age, until 50 years old. The highest prevalence rate of ALD was found in people 
40–49 years old47. The age differences between each demographic region are likely due to 
the care setting from which data were collected (population vs hospital-based), age structure 
of the population itself, and patterns of alcohol consumption. In fact, there were no 
differences in the mean age of hospitalized ALD patients in each geographic location48–50.
The greater vulnerability of women and lower safe limits for consumption have long been 
recognized25. However, cases reported from each geographic region have indicated a higher 
prevalence of ALD and mortality in men2,35, 36, 46, 49. This could be because men typically 
drink more than women, have a greater proportion of heavy drinkers and alcoholics, 
regardless of geographic locations51. The longstanding sex difference in alcohol 
consumption has decreased in Western countries. In the UK, mortality from ALD has 
increased more in women than in men with a 7-fold increase in women younger than 30 
years41.
Socioeconomic status
Rising income among people in the developing world increases their access to alcohol and in 
turn, associated morbidities, including ALD52, 53. However, the link between socioeconomic 
status and ALD is complex. Multiple factors are involved, such as market liberalization, 
increased advertising, and growing affluence; these have made alcohol more available in 
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general54 and to people of low socioeconomic status, in particular55. Alcohol-related 
problems have increased rapidly in this group. One study found significant increases in risks 
of cirrhosis-associated mortality among patients who are not married or are urban residents, 
unemployed, or with lower levels of education and family income56. An analysis of the US 
National Inpatient Sample showed that patients hospitalized for AH come primarily from 
low-income households36. In China, the production and consumption of alcoholic beverage 
have increased with the country’s rapid economic growth9, 47. A study from North-Eastern 
China showed that that people with a low level of education or income, or people who are 
unmarried, have a high risk of ALD47. The findings which are similar to those reported from 
the US56.
Race and ethnicity
There are few data on the effects of race and ethnicity on alcohol-associated disease from 
Asian countries, primarily because of their homogenous populations. In the US, age-
adjusted rates of alcohol-associated cirrhosis are higher for Blacks than for Whites51, and 
mortality is highest in Hispanic groups57. However, these findings cannot be attributed to 
higher alcohol consumption among Hispanics and Blacks than Whites51—alcohol 
consumption among Blacks has been less than or comparable with that of Whites. The 
reasons for the differences in cirrhosis and mortality are not clear, but could involve the 
limited access of Blacks and Hispanics to alcohol rehabilitation, or hepatitis C virus 
infection, which is more common in Hispanics51.
Body mass index (BMI) and obesity
In an epidemiologic study from the US, overweight and obesity were found to increase risk 
for alcohol-related abnormalities in aminotransferase activity58. A large study from France 
identified excess body weight for at least 10 years as a risk factor for AH and alcohol-
associated cirrhosis35. A study from Scotland found that high BMI and excessive alcohol 
intake increased mortalities from liver disease59. Similar observations have been made in 
studies in Asia. In a large prospective study of 1270 subjects from China, 16% had BMI ≥ 
25 kg/m2. Though the average daily alcohol intake in this group was lower than those with 
BMI<25, ALD morbidity in this group was 11.5%, compared to ~5% in those with normal 
BMIs. The presence of obesity was an independent predictor for ALD60.
Genetic factors
Variants in genes encoding members of the alcohol dehydrogenase (ADH) family affect their 
ability to metabolize alcohol. Levels of ADH enzymatic activity determine risk for alcohol 
dependence and susceptibility to alcohol-induced liver injury30. Individuals carrying variants 
that encode enzymes with high levels of activity (ADH1B*2 and ADH1C*1 alleles) are 
believed to be at increased risk for ALD, due to higher levels of acetaldehyde exposure61. In 
a Japanese cohort of alcoholic men, the ADH1B*2 allele was associated with greater risk of 
cirrhosis compared with the ADH1B*1 allele62. However, a large study of 876 Caucasian 
individuals (from Spain, France, Germany, Sweden, and Poland) did not detect a significant 
association between ADH1C variants and alcohol-associated cirrhosis, although it did find 
that ADH1B*2 reduced risk for excessive alcohol intake63. A recent meta-analysis 
confirmed this association in Asian populations but found no association in Western 
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populations64. This could be because ADH1B*2 is a rare allele in Caucasians; some smaller 
studies found no patients to carry this allele. Approximately 40%–50% of Chinese people 
are homozygous or heterozygous for the ALDH2*2 allele and have low ALDH2 activity65. 
These individuals have high blood concentrations of acetaldehyde after alcohol consumption 
and may be more susceptible to liver injury.
Alcohol can be metabolized, to a lesser extent, by cytochrome P450 family 2 subfamily E 
member 1 (CYP2E1). CYP2E1 is an inducible enzyme; its activity can increase up to 20-
fold following continuous alcohol consumption66. The c1 and c2 alleles of CYP2E166 affect 
activity of the gene product. The product of the CYP2E1*5 (c2) allele has higher activity 
than that of c1 allele, and could lead to a higher exposure of the liver to acetaldehyde and 
reactive oxygen species67. In a study of a Caucasian population in the West, the c2 allele 
was associated with increased risk of ALD in subjects with higher cumulative levels of 
alcohol consumption. However, the risk was only in subjects who also had the ADH1C*2 
allele68. Interestingly, another polymorphism in CYP2E1, Taq I, is associated with reduced 
susceptibility to ALD, although this allele does not directly affect alcohol metabolism69. 
Several studies from Japan and Korea have searched for associations between the 
polymorphisms in CYP2E1 and ALD without positive results70, 71. A study of Chinese of 
Han, Mongol, and Chaoxian nationalities found a positive association between the c2 
genotype and ALD72.
Altered activities of cytokines and proteins that respond to endotoxin are involved in the 
pathogenesis of ALD73, so variants in their genes could affect susceptibility to ALD. CD14 
is a coreceptor for the toll-like receptor 4, which interacts with bacterial lipopolysaccharide 
in the portal bloodstream74, 75. A C/T polymorphism at position −159 in the promoter region 
of the CD14 gene, producing a TT genotype, is associated with increased expression of 
CD1476. In a study of autopsy results from 442 men in Finland, with valid alcohol 
consumption data, the TT genotype increased risk for advanced ALD by almost 2.5-fold and 
cirrhosis by almost 3.5-fold, compared to men without the TT genotype77. Individuals with 
the TT polymorphism at position −159 in the promoter region of the CD14 are therefore at 
high for cirrhosis77. Interestingly, a study from Taiwan did not associate this polymorphism 
with ALD78.
A C/A polymorphism at position −627 in the promoter of the interleukin-10 (IL10) gene has 
been associated with decreased expression, resulting in an increase inflammatory 
response79. Researchers investigated the prevalence of this polymorphism among 287 heavy 
drinkers with biopsy-proven advanced ALD, 107 heavy drinkers with no evidence of liver 
disease or steatosis from biopsy analyses, and 227 individuals without liver disease 
(controls). At this position in IL10, 50% of patients with advanced ALD had a least 1 allele 
with the A C/A polymorphism, compared with 33% of controls and 34% of drinkers with no 
or mild disease. These findings indicate an association between genetic variants that reduce 
expression or activity of IL10 and ALD79. However, subsequent studies of polymorphisms 
in IL10 in other European populations produced contradictory results80, 81. A study from the 
Bengali population of Eastern India associated a genetic variant of IL10 with alcoholic 
cirrhosis82 as did smaller study from Taiwan83.
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The patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene is located on 
the long arm of chromosome 22 and encodes adiponutrin. This protein has triglyceride 
lipase and acylglycerol transacetylase activities, and is expressed in response to energy 
mobilization and storage of lipid droplets84. A genome-wide screen for non-synonymous 
single nucleotide polymorphisms in Hispanic, African, and European Americans 
participating in the Dallas Heart Study associated a variant in PNPLA3 (rs738409 [M148I]) 
with hepatic fat content, measured by proton magnetic resonance spectroscopy85. PNPLA3 
rs738409 increased risk for alcoholic cirrhosis 2.25-fold86. The association between 
PNPLA3 variants and ALD was confirmed in a German cohort87 and patients with alcohol-
associated cirrhosis of European descent88. In this study, carriers of PNPLA3 rs738409 
(G/G) were found to be at high risk for progression of clinically silent to overt ALD. In total, 
26.6% of the population-attributable risk for the progression of early to advanced ALD were 
found to be conferred by this risk allele87. A recent meta-analysis clearly associated the 
rs738409 variant with alcoholic liver cirrhosis89. A number of studies have associated 
variants in PNPLA3 with non-alcoholic fatty liver disease in different regions of Asia90, 91 
but there are few data on ALD92. A small study from India (of 60 patients with alcohol-
associated cirrhosis) found that the rs738409 polymorphism increased risk for ALD 2.1-
fold92. However, further studies are needed to determine the association between PNPLA3 
and ALD in Asian populations.
Clinical Presentation
We have no evidence to support significant differences in the clinical presentation of ALD 
among patients in Asia, Europe, or North America. Most patients present with signs and 
symptoms related to portal hypertension or cirrhosis. Jaundice, as expected, is common 
among patients presenting with AH93.
Treatment of AUD
The most powerful determinants of alcohol use are price, availability, and promotion. Public 
policies that address these factors can influence population level use of alcohol and in turn 
rates of cirrhosis and other health disorders. The WHO has endorsed a global strategy to 
reduce harmful use of alcohol that includes 10 priority actions for nations (see Fig 3) and 4 
international priority actions94. However, the strength of public policy varies strikingly 
among nations and over time.
Internationally, there is evidence that strength of public policy correlates with levels of 
consumption95. For example, during the alcohol prohibition era in the USA, cirrhosis 
mortality was reduced by approximately half51. In Russia, alcohol-attributable mortality 
varied by year as national controls were imposed and relaxed; in several recent years, 
alcohol caused more than half of all deaths among Russians 15–54 years old96. Current 
policies in China and India promote increased use—alcohol is cheap and there is widespread 
access to high-strength alcoholic beverages97. As prosperity has increased, the global 
alcohol industry has increased its focus on sales in these regions, but this may have adverse 
effects on health. Many believe that the alcohol industry is currently focusing on women and 
young people98, who are most vulnerable to alcohol-related disorders, including ALD. 
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China has implemented several changes in alcohol taxes, for general economic reasons, and 
these have been linked to changes in both consumption and alcohol-associated harm99. 
These policy approaches could reduce the burden of ALD, but a recent review reported a 
dearth of alcohol policy research in China100. An increase in alcohol tax in Taiwan in 2002 
reduced hospital expenditures on ALD101.
There has been a recent significant review of the effects of ALD and liver disease in general 
in the UK42. The review recommended a minimum price on alcoholic beverages—
particularly for cheap wine—health warnings on packages (similar to tobacco), a volume-
based tax, reduction in the number of liquor outlets, restrictions on advertising, and 
improved screening and access to treatment for alcohol problems42. Such policies have been 
introduced in some European countries. However, there seems to be resistance in the UK to 
their implementation—it has been proposed that this is related to pressure on government 
from the alcohol industry. Similar recommendations have been made elsewhere, and there 
has been comparable reluctance to introduce alcohol control policies in India98, China11, 
and the US102.
Alcohol use can be detected by clinical and laboratory tests, but screening instruments for 
alcohol disorders have been developed; these are more sensitive than routine care and are 
cheap and readily available. The AUD Identification Test (AUDIT) developed by the WHO 
in the 1990s is the most widely used but was validated in the English language. AUDIT has 
been translated and validated into a number of languages including Tamil103, Konkani (the 
language of Goa)104, Chinese105, and Korean106. Other screening measures have not been 
disseminated into many languages other than English.
The most widely available treatment involves provision of brief advice to reduce or stop 
drinking. Many patients with ALD may have little evidence of a severe AUD and may not 
require formal treatment. Structured brief interventions have been shown to be effective in a 
range of clinical settings, including for patients with liver disease, and may be repeated 
during long-term follow up107. Brief intervention does not require specialist skills and can 
be provided by any credible health care provider. An Indian study is exploring use of lay 
counsellors108 and if successful, will allow widespread dissemination of this intervention at 
lower cost. Many alcohol brief interventions have been made available online in recent years 
but are largely in the English language to date.
Treatment of ALD
Pharmacologic treatments for ALD are limited in efficacy, apart from corticosteroids for 
life-threatening AH109. The use and indications for corticosteroids in different geographic 
regions do not seem to differ. However, there is much interest in India in the use of 
granulocyte colony stimulating factor (GCSF) in treatment of patients with acute on-chronic 
liver failure of which ALD is the predominant cause. Surprisingly, GCSF increased survival 
times, by a small amount, in patients with AH110. A larger randomized trial is underway in 
India to determine the efficacy of GCSF in the management of steriod non-responsive severe 
AH111.
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Medicines to reduce relapse to heavy drinking are less widely used in the Asia than in 
Europe and the US. In China, treatment approaches differ from the West, because some 
drugs are not available, and involve use of traditional Chinese medicines and 
acupuncture112. Challenges to treatment in the West include limited access to treatment, 
stigma, and limited training of health care professionals112.
Liver transplantation for patients with ALD is accepted internationally; ALD has been a 
leading indication in Europe and the US and has been increasing in China113. Currently, 
7.5% of all liver transplants go to patients with ALD47. Most liver transplants in the East 
come from living related donors114. In general, assessment principles are similar to those of 
Western countries47, 115. Survival times following transplantation seem to be similar in the 
East vs West116. However, a report from 38 Japanese centers found that mortality associated 
with recidivism was particularly high compared to reports from the West117.
Ethical concerns about liver transplantation in China have been raised and are progressively 
being addressed97. The overall system to provide adequate access to evidence-based care 
that integrates health problems is still evolving in many parts of the world. An integrated 
approach that combines medical care with psychosocial treatment for AUD is more effective 
at maintaining abstinence118. A study from Korea highlighted the difficulty in establishing 
this system of care for patients with AUD119. This may also be a challenge to implement 
broadly in Western nations.
Future Directions
There are worldwide differences in the prevalence of ALD, as well as in mortality, 
treatment, and the factors that contribute to development of ALD. It is undeniable that the 
ALD will continue to be a major cause of morbidity and mortality throughout the world. 
Global strategy and public policy to reduce harmful use of alcohol use and effective 
therapies for ALD are needed.
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Figure 1. 
Total adult per-capita consumption of pure alcohol in Asia, Europe, and North America 
(modified from ref 13)
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Figure 2. 
Overall alcohol-attributable deaths caused by cirrhosis in different geographic regions 
(modified from ref 2)
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Figure 3. 
WHO Global Strategy to Reduce Harmful us of alcohol (modified from ref 94)
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